PRaG therapy before surgery for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new combination treatment (PRaG therapy) for patients with locally advanced pancreatic cancer that has not spread. It aims to help shrink the tumor so it can be removed surgically, and it is for patients who have not had prior radiation, chemotherapy, or immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic ductal adenocarcinoma (a common type of pancreatic cancer), and the tumor is in the head, neck, or body of the pancreas.
- Your cancer is locally advanced (has not spread to other parts of the body) and is either borderline removable or cannot be removed with surgery right now.
- You are in good overall health (able to carry out daily activities without help, with a life expectancy of at least 3 months).
- You have not had radiation to the belly, chemotherapy, or immunotherapy (PD-1/PD-L1 drugs) before.
- Your blood counts, liver and kidney function are within acceptable ranges (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to combine two types of radiation therapy (called PRaG-1 and PRaG) for people with advanced solid tumors that have few treatment options. The goal is to see if this approach can help your immune system fight the cancer better.
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
This trial tests if adding radiation and an immunotherapy drug (serplulimab) to standard chemotherapy can help people with pancreatic cancer that has come back or spread. It is for those who haven't had prior treatment for advanced disease.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests whether combining radiation therapy with chemotherapy (called the GX regimen) after pancreatic cancer surgery helps prevent cancer from returning in patients with high-risk features. The study aims to see if this combination treatment improves outcomes compared to standard care.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.